Alligator Bioscience AB

ST:ATORX Sweden Biotechnology
Market Cap
$9.42 Million
Skr105.73 Million SEK
Market Cap Rank
#36661 Global
#603 in Sweden
Share Price
Skr0.20
Change (1 day)
+4.66%
52-Week Range
Skr0.01 - Skr7.20
All Time High
Skr55.78
About

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, develo… Read more

Alligator Bioscience AB (ATORX) - Total Liabilities

Latest total liabilities as of December 2025: Skr103.74 Million SEK

Based on the latest financial reports, Alligator Bioscience AB (ATORX) has total liabilities worth Skr103.74 Million SEK as of December 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Alligator Bioscience AB - Total Liabilities Trend (2005–2025)

This chart illustrates how Alligator Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Alligator Bioscience AB Competitors by Total Liabilities

The table below lists competitors of Alligator Bioscience AB ranked by their total liabilities.

Company Country Total Liabilities
Omkar Speciality Chemicals Limited
NSE:OMKARCHEM
India ₹2.43 Billion
PAYCHEX INC - Dusseldorf Stock Exchang
DU:PCX
Germany €6.64 Billion
SHAREHOLD VAL BET N (SVE.SG)
STU:SVE
Germany €2.26 Million
ANGLO AM PLATINUM
MU:RPHA
Germany €69.18 Billion
TEXAS CAP BANC
MU:TCA
Germany €28.28 Billion
SHAREHOLD VAL BET. - Dusseldorf Stock Exchang
DU:SVE
Germany €2.26 Million
Monarch West Ventures Inc.
V:MONA-P
Canada CA$2.28K

Liability Composition Analysis (2005–2025)

This chart breaks down Alligator Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.88 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.80 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 15.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.94 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Alligator Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Alligator Bioscience AB (2005–2025)

The table below shows the annual total liabilities of Alligator Bioscience AB from 2005 to 2025.

Year Total Liabilities Change
2025-12-31 Skr103.74 Million -55.84%
2024-12-31 Skr234.93 Million +120.39%
2023-12-31 Skr106.59 Million +32.36%
2022-12-31 Skr80.53 Million +58.13%
2021-12-31 Skr50.93 Million +38.79%
2020-12-31 Skr36.69 Million -30.28%
2019-12-31 Skr52.63 Million +32.08%
2018-12-31 Skr39.85 Million +58.89%
2017-12-31 Skr25.08 Million +1.96%
2016-12-31 Skr24.59 Million +27.52%
2015-12-31 Skr19.29 Million -34.12%
2014-12-31 Skr29.27 Million +221.31%
2011-12-31 Skr9.11 Million +7.85%
2010-12-31 Skr8.45 Million +21.24%
2008-12-31 Skr6.97 Million +8.72%
2007-12-31 Skr6.41 Million +0.39%
2006-12-31 Skr6.38 Million -52.52%
2005-12-31 Skr13.45 Million --